Market Research Future (MRFR)’s study Reveals that the “Global Erythropoietin Drug Market”, the report offers detailed Analysis about the Top Trends and Current Scenario with competitive landscape and key regions development status.
Global Erythropoietin Drug Market – Overview
Erythropoietin drugs are also known as hematopoietin. It is a glycoprotein hormone that controls erythropoiesis or production of RBC. They are used in treatment of different diseases like cancer, chronic renal diseases, AIDS, anaemia and many more. Increasing prevalence of diseases like cancer, AIDA and renal diseases are the major drivers for the growth of the erythropoietin market. Moreover, introduction of new drugs and different government initiatives for research fuels the market growth during the forecast period. However, high cost of treatment along with the related side effects of the may restrain the growth of market growth during the forecast period.
Get Sample Report at https://www.marketresearchfuture.com/sample_request/1360
Erythropoietin Drug Market is growing with the rapid pace. According to a recent study report published by the Market Research Future, global erythropoietin drug market is booming and expected to gain prominence over the forecast period. The market is projected to demonstrate a spectacular growth by 2023, surpassing its previous growth records in terms of value with a striking CAGR during the anticipated period (2017 – 2023).
Global Erythropoietin Drug Market - competitive Analysis
Hoffmann-La Roche (Switzerland), Johnson & Johnson (US), Amgen (US), Kyowa Hakko Kirin, Intas Pharmaceuticals (India), Teva Pharmaceutical Industries Ltd. (Israel), Biocon (India), Emcure Pharmaceuticals (India), Celltrion, Inc. (South Korea), Hospira (US), Dahua Pharmaceutical (China), LG Life Sciences Ltd. (Korea), 3SBio, Boehringer Ingelheim (US), BIOSIDUS (Argentina) are the prominent players at the forefront of competition in the Global Erythropoietin Drug Market and are profiled in MRFR Analysis.
Characterized by the presence of several well-established and small players, global erythropoietin drug market appears to be a highly competitive and fragmented market. International players who are increasingly expanding their footprint in the developing economy, making it difficult for regional vendors to compete with them, especially in terms of features product portfolios, quality, and pricing. The market is witnessing intensified competition which is expected to get more intensified further during the forecast period. The intense competition prevalent in the market dictates the consolidation among marketers.
Well established players incorporate acquisition, collaboration, partnership, expansion, and product launch in order to gain competitive advantage in this market and to maintain their market position.
Amgen Inc. is one of the major player in the global erythropoietin drug market and is headquartered in the US. In April-2017, Amgen Inc. expanded their commercial collaboration with Novartis for erenumab, which is being investigated for the prevention of migraine. This expanded commercial collaboration was built on a global neuroscience collaboration in Alzheimer's disease and migraine established in 2015 between Novartis and Amgen. This expanded collaboration leveraged Novartis' strong and established presence in neuroscience to more effectively reach people with migraine.
In Jan-2017, Sanofi and Boehringer Ingelheim confirmed that the strategic transaction signed in June 2016, which consisted of an exchange of Sanofi’s animal health business (Merial) and Boehringer Ingelheim’s consumer healthcare (CHC) business, has been successfully closed in most markets on January 1st 2017. This closing marks the successful outcome of the business swap which started with exclusive negotiations in December 2015. The closing of the acquisition of Merial in Mexico and the Merial and CHC swap in India have been delayed pending receipt of certain regulatory approvals but both are expected to close early 2017.
In Aug-2016, Teva Pharmaceutical Industries Ltd. and Allergan plc completed their acquisition of Allergan’s generics business. This strategic acquisition brought together two leading generics businesses with complementary strengths, R&D capabilities, product pipelines and portfolios, geographical footprints, operational networks and cultures. The result is a stronger, more competitive Teva, well positioned to thrive in an evolving global marketplace, to realize the opportunities the very attractive global and U.S. generics markets offer.
Global Erythropoietin Drug Market - Regional Analysis
The Americas leads global erythropoietin drug market due to a well-developed healthcare sector, huge patient population and rising healthcare expenditures within the region. The Americas is followed by Europe in the presence of the similar factors facilitating the market growth within the region. Asia Pacific is the fastest growing region due to a huge patient population and continuously growing healthcare sector by the developing economies like India and China. Additionally, rising government support facilitates the market growth within the region. On the other hand, Middle East & Africa have the least share of the market, especially due to the presence of the presence of poor economies and stringent government policies within the African region.
Get Full Report at https://www.marketresearchfuture.com/reports/erythropoietin-drug-market-1360
About US:
Market Research Future (MRFR) enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
Phone: +1 646 845 9312
